by Madaline Spencer | Dec 10, 2025
Jonathan Barratt, Mayer Professor of Renal Medicine at the University of Leicester, discusses interim results from a study testing mezagitamab for the treatment of immunoglobulin A (IgA) nephropathy. IgA nephropathy is a kidney disorder that occurs when IgA...
by Madaline Spencer | Dec 9, 2025
Kim Moran, Head of U.S. Rare Diseases at UCB, discusses the approval of Kygevvi (doxecitine and doxribtimine) for patients with thymidine kinase 2 deficiency (TK2d). TK2d is a rare genetic disease characterized by progressive and severe muscle weakness....
by Madaline Spencer | Dec 8, 2025
Michelle Rheault, MD, Pediatric Nephrologist at the University of Minnesota, discusses data from the DUPLEX study testing sparsentan to treat patients with focal segmental glomerulosclerosis (FSGS). FSGS is a rare kidney disorder characterized by...
by Madaline Spencer | Dec 6, 2025
The U.S. Food and Drug Administration (FDA) has approved Voyxact (sibeprenlimab) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. IgAN is a kidney disorder that occurs when IgA protein...
by Madaline Spencer | Dec 5, 2025
The U.S. Food and Drug Administration (FDA) has approved Itvisma (onasemnogene abeparvovec) for the treatment of patients ages two years and older with spinal muscular atrophy (SMA) with a confirmed mutation in the SMN1 gene. The gene therapy is administered...
